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Background: Substitutions of amino acid (aa) 70 in the core region of hepatitis C virus genotype 1b (HCV 1b) are a
predictor of the non-virological response to pegylated interferon plus ribavirin (PEG-IFN/RBV) therapy. The aim of
our study was to develop quantitative real-time reverse transcription polymerase chain reaction (qPCR) assays to
quantify wild-type (70 W) and mutant (70 M) strains of HCV 1b.
Methods: We used the TaqMan system to quantify strains 70 W and 70 M. Codon 70 in the HCV 1b core region
can be either CGN or CAN, therefore degenerate TaqMan minor groove binder (MGB) probes with inosine were
used. We determined detection limits, sensitivity and specificity of the methods developed. Direct sequencing and
cloning of the HCV core region were used to confirm the reliability of our new system. Serum samples from 138
Chinese patients infected with HCV 1b were examined with the system we developed and compared with results
obtained from the Roche TaqMan RT-PCR HCV RNA quantitation system.
Results: Degenerate MGB probes were able to clearly distinguish 70 W from 70 M. The detection limit was
103 copies/mL. Cross-reactivity tests confirmed the specificity of our method. Our system can effectively quantify
70 W and 70 M for 99.6% of patients with HCV 1b. Further tests involving cloning and sequencing confirmed the
reliability of our system.
Conclusions: We developed an assay system using degenerate TaqMan MGB probes with inosine to quantify
wild-type and mutant viral RNAs of the HCV 1b core region at aa 70. Our developed assay system had high levels
of sensitivity and accuracy, and could prove useful in investigating dynamic changes during PEG-IFN/RBV therapy to
assess virological responses.
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Quantitative PCRBackground
Hepatitis C virus (HCV) infection represents a major
public health problem as it is a major cause of chronic
hepatitis. Considerable numbers of HCV patients develop
liver cirrosis and hepatocellular carcinoma (HCC). Over
the last 20 years, several antiviral drugs have been devel-
oped to treat chronic hepatitis C, including pegylated
interferon (PEG-IFNα), ribavirin (RBV) and direct-acting
antivirals (DAAs). Until 2011, the combination of PEG-
IFNα and RBV (PEG-IFNα/RBV) was the approved
treatment for chronic hepatitis C [1]. New therapeutic
strategies with DAAs aim towards higher efficacy,* Correspondence: yfcyt@139.com
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unless otherwise stated.pan-genotypic activity, shortened treatment duration,
easier administration and improved tolerability and
patient adherence [2].
IFN-sparing and -free regimens with or without ribavi-
rin will enter clinical practice in the next few years.
However, in some developing countries, such as China,
or in some rural and poor regions, use of PEG-IFNα/
RBV still represents a standard treatment approach and
is sometimes the only available therapy. The long-term
response to this therapy remains unsatisfactory, especially
in patients infected with HCV genotype 1b (HCV 1b).
Additionally, PEG-IFN/RBV combination therapy is ac-
companied by adverse events. Prediction of the re-
sponse to antiviral treatment before initiation or in the
early phase of therapy would be advantageous. SeveralThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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RBV therapy; some are associated with the host, such as
interleukin 28B single nucleotide polymorphisms (IL28B
SNPs), gender, race, age, and obesity [3-7], while some are
virus-associated, such as viral genotype, viral load, amino
acid (aa) substitution in the core and non-structural (NS)
5A region [8-10].
Substitution at aa 70 of the core protein is one of the
most important factors, along with IL28B polymorphisms
[11-15]. For patients with the IL28B rs8099917 genotype,
12% of those with Gln70 (His70) had a sustained viral re-
sponse (SVR), while 50% of patients with Arg70 were con-
ferred an SVR [16]. Detection of aa 70 substitutions is
important to predict an early non-virological response
(NVR) and is also the basis to study the mechanisms of
IFN treatment resistance. To investigate wild-type (Arg70;
70 W) and mutant (Gln/His70; 70 M) strains of HCV 1b,
several methods are available including direct sequencing,
mutation-specific polymerase chain reaction (PCR) assays
[17] and quantitative PCR assays [18]. However, the sensi-
tivity and specificity of these tests are limited. These
methods are insufficient for quantifying viral RNAs and
cannot be used to investigate the dynamic response of
70 W and 70 M to antiviral therapy.
We attempted to develop an absolute quantitation sys-
tem for 70 W and 70 M using degenerate TaqMan minor
groove binder (MGB) probes with inosine. We also sought
to determine the sensitivity, specificity, and reproducibility
of our improved system and correlate our results with
those from direct sequencing and cloning sequencing.
Results
Specificity of probes and optimization of qPCR assays
Probes could detect plasmid templates with one-base
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Figure 1 Quantitation of serial 10-fold dilutions of 70 W and 70 M pla
B. Mutant probe.that when well-matched plasmids were used. When 5 ×
107 copies of the wild-type plasmids (CGG of codon 70)
were tested using the mutant probe (CAI), which had a
base mismatch, approximately 30 cycles were required
before the crossing threshold was reached (Figure 1A).
This compares with 15 cycles for the matching probe
(CGI). When fewer than 5 × 102 copies of the wild-type
plasmid were tested using the mutant probe, no signal
was detected by 45 cycles. All serial dilutions of the tem-
plates could be detected by the matched probe by 41 cy-
cles. When 5 × 107 copies of the mutant plasmid (CAG
of codon 70) template were used in conjunction with the
wild-type probe (CGI), approximately 34 cycles were re-
quired before the crossing threshold was reached, while
only 17 cycles were required for the matching probe
(CAI). When fewer than 5 × 103 copies of the mutant
plasmid were tested with the wild-type probe, no signal
was detected by cycle 45. All serially diluted templates
could be detected by the matching probe in 42 cycles
(Figure 1B). The slope of the curve for Rn vs. cycles for
the mismatched reaction was lower than that of the
well-matched reaction.
To eliminate the impact of non-specific amplifications,
when qPCR assays were prepared, a cross-reaction con-
trol with 5 × 107 copies of a one-base mismatch plasmid
was used. When data were analyzed, a manual baseline
was used to cover the curve vertex of the cross-reaction
control to ensure specificity of the system.
Sensitivity and detection limits of the probes
The wild-type and mutant plasmids were mixed at ratios
of 99:1, 90:10, 80:20, 50:50, 20:80, 10:90, and 1:99, corre-
sponding to final concentrations of 107–101 copies/μL.
Using the plasmid mixture as a template, qPCRs were per-
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http://www.virologyj.com/content/11/1/148detect 1% of wild-type plasmids in the 100 copies/μL mix-
ture, or 10% for the 10 copies/μL mixture (Table 1). Simi-
larly, 1% of the mutants among the 100 copies/μL mix, or
10% of the 10 copies/μL mixture, were successfully de-
tected with the mutant probes. The calculated relative ra-
tios agreed with those of the template plasmids (Figure 2).0%
20%
40%














Ratios of wild type to mutant plasmids
Figure 2 Relative ratios of wild-type to mutant as determined
by the novel detection system.Quantitation of aa 70 substitutions in clinical samples
HCV 70 W and 70 M in serum samples from 138 Chinese
patients with HCV 1b were successfully quantified. Se-
quences from the HCV core region were confirmed by
direct sequencing. Using relative ratios, we identified
three categories to compare by direct sequencing: less
than 1% (wild-type); 1–99% (mixed); and greater than
99% (mutants; Table 2). We found a mix of genotypes in
94% (129/138) of samples. Approximately 68% (88/129)
of cases could be detected only by our novel system.
The mutant strain was dominant (>50%) in 23% (32/138)
of patients.Accuracy of our novel system
When the system with normal TaqMan MGB probes
was used, 89.1% (123/138) of the sums of wild-type and
mutant viral loads were comparable with results from
the Roche diagnostic system (Table 3). In 15 cases, the
results were less than 20% of those from the Roche sys-
tem. When our improved system with degenerate probes
was used, only a single patient’s result was not compar-





101 102 103 104 105 106 107
Wild-type
99:1 D D D D D D D
90:10 D D D D D D D
80:20 D D D D D D D
50:50 D D D D D D D
20:80 D D D D D D D
10:90 D D D D D D D
1:99 U D D D D D D
Mutant
99:1 U D D D D D D
90:10 D D D D D D D
80:20 D D D D D D D
50:50 D D D D D D D
20:80 D D D D D D D
10:90 D D D D D D D
1:99 D D D D D D D
W:M, ratio of wild-type to mutant plasmids.
D, detectable.
U, undetectable.Direct sequencing of the core region showed that 83.3%
(115/138) of patients’ core genes completely matched
primers used in our novel system. We also found that the
core genes in 23 patients contained one or two mis-
matched sites with the primers. However, only one mis-
matched site (G162A) was near the 3′ end of the sense
primer. For the other 22 cases, the mismatched sites were
near the 5′ ends of the sense (A154G, C159T) or antisense
(A297G/T, C300T, G302A) primers and exerted very little
influence on the PCR results. For 89.9% (124/138) of
cases, the major codon 70 types were CGG or CAG; for
the other 14 cases, they were CGA, CGT, CAA, CAT,
or CAC.
Accuracy of ratios for wild-type to mutant viral loads
The 14 cases with codon 70 types other than CGG or
CAG were selected for TA cloning and sequencing. Our
results showed that the ratios of wild-type to mutants as
determined by our novel system were comparable with
those from the cloning and sequencing experiments. For
patients with codon 70 types other than CGG and CAG,Table 2 Prevalence of aa 70 substitutions in 138 Chinese
patients with HCV 1b who had not been treated
Core 70 mutant (%) Direct sequencing
Wild-type Mixed Mutant
<1 5 0 0
1-10 43 0 0
10-15 13 1 0
15-20 2 6 0
20-30 1 12 0
30-40 1 14 0
40-50 0 8 0
50-80 0 0 0
80-90 0 0 1
90-99 0 0 27
>99 0 0 4
Table 3 Ratio of HCV RNA loads as determined by novel
systems with degenerate probes or normal MGB probes








<2 94 (68.1) 121 (87.7)
2–5 29 (21.0) 16 (11.6)
>5 15 (10.9) 1 (0.7)
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fix the errors caused by normal probes (Table 4).
Discussion
The study presented here is based on reports that substi-
tution of arginine by glutamine at aa 70 in the HCV 1b
core region is an independent and significant marker asso-
ciated with an NVR to PEG-IFN/RBV therapy. A signifi-
cant association between HCV core91 substitutions and
treatment outcome has been reported in several studies
[8,19]. However, other studies have described that only a
variation at residue 70 is associated with treatment re-
sponse. The aa 70 substitution has been identified as the
most important factor for PEG-IFN/RBV treatments with
the exception of IL28B polymorphisms [3,12,13,16].
Direct sequencing is the most accurate method for de-
termining aa 70 substitutions, but sensitivity is limited
for samples with mixed genotypes. A minor genotype
present at levels of about 15–20% might not be detected
by direct sequencing. Direct sequencing is not able toTable 4 Correlation of results from the novel system with deg
system, and from sequencing
No. Roche system Normal probes Degenerate probes
RNA Load$ Ratio* Wild-type (%) Ratio* Wild-type (%)
1 7.2 0.19 82.1 1.33 98.5
2 6.3 0.01 0.0 1.27 2.6
3 7.0 0.08 4.2 1.38 92.0
4 6.6 0.07 100.0 0.71 97.5
5 6.6 0.08 100.0 0.87 100.0
6 5.6 0.17 4.8 1.39 2.7
7 6.5 0.02 63.2 0.70 92.7
8 7.9 0.04 0.0 0.80 0.0
9 7.1 0.03 2.0 1.48 1.5
10 6.4 0.13 20.6 1.47 4.2
11 5.6 0.12 95.6 1.18 96.4
12 7.4 0.08 96.0 1.32 8.0
13 6.7 0.08 91.3 0.96 9.8
14 6.3 0.18 95.5 1.90 97.5
$RNA loads (Log10 copies/mL) as determined by the Roche Diagnostic System.
*Ratio of RNA loads (copies/mL) as determined by our novel system to those determ
#No data available.quantify virus RNAs and cannot be used to investigate
the dynamic response to antiviral therapy of wild-type
and mutant strains. Because the sequencing method is
costly, Okamoto et al. [17] developed a new method,
the amplification refractory mutation system (ARMS)
reverse transcription PCR (RT-PCR), and this became
widely adopted. In the HCV 1b core region, several co-
dons encode arginine (CGG/C/U/A) in wild-type proteins;
however, the second base is always a “G”. Similarly, the
second base of the codon encoding glutamine or histidine
(CAG/C/U/A) in mutant proteins is always an “A”. Thus,
detection of wild-types or mutants based on a single-base
difference can be achieved by designing the common sec-
ond base (A or G) at the 3′ end of primers. Compared
with direct sequencing, the mutation-specific PCR is sim-
pler, quicker, and more convenient with a satisfactory
detection rate, frequency of competitive-type cases, and
re-examination rate. However, the authors also pointed
out that the system excludes the presence of a minor
type. Detailed examination, such as sequence analysis
using cloning, might be necessary when a competitive
type is indicated by the detection system. Moreover, the
system is unable to quantify virus RNAs. To quantify
the aa 70 mutations, Nakamoto et al. [18] developed a
real-time ARMS RT-PCR assay. Mutation-specific primers
are able to distinguish the difference between wild-type
and mutant plasmids at the same quantitative levels.
The real-time ARMS RT-PCR is more convenient be-
cause it uses a fluorescent signal instead of restriction en-
zyme digestion, gel electrophoresis, or sequence analysisenerate probes, normal probes, the Roche diagnostic




4CGG/1CAG/14CGA/1 N.D.# 4CGG/1CAG 18CGN/1CAN
13CAA/7CAT None 20CAN
2CAG/18CGA 2CAG 2CAN/18CGN
15CGA/5 N.D. None 15CGN
1CGG/19CGT 1CGG 20CGN
3CAG/17CAA 3CAG 20CAN
2CAA/16CGA/2 N.D. None 2CAN/16CGN
18CAA/2 N.D. None 18CAN
19CAC/1 N.D. None 19CAN
1CGG/3CAG/16CAA 1CGG/3CAG 1CGN/19CAN
3CGG/17CGA 3CGG 20CGN
1CGG/15CAT/4 N.D. 1CGG 1CGN/15CAN
2CGG/16CAA/2 N.D. 2CGG 2CGN/16CAN
4CGG/16CGA 4CGG 20CGN
ined by the Roche Diagnostic System.
Table 5 Frequencies of possible primer mismatches based
on 489 sequences of the HCV 1b core gene
Sense primer Anti-sense primer
nt 5′ Frequencies of
mismatch (%)
nt 5′ Frequencies of
mismatch (%)
148 A 0.00 302 C 1.64
149 G 0.20 301 G 0.20
150 G 0.41 300 G 3.07
151 A 0.00 299 G 0.00
152 A 0.00 298 G 0.00
153 G 0.20 297 T 7.98
154 A 0.61 296 G 0.00
155 C 0.00 295 A 0.20
156 T 0.00 294 C 0.20
157 T 0.20 293 A 0.20
158 C 0.41 292 G 0.61
159 C 2.04 291 G 0.20
160 G 0.00 290 A 0.00
161 A 0.41 289 G 0.20
162 G 0.41 288 C 0.00
163 C 0.00 287 C 0.00
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proportion of core substitutions. The specificity of the sys-
tem is dependent upon the mutation-specific primers; a
minor genotype might be masked when the ratio is less
than 1:100. Furthermore, with the SYBR Green method,
primer dimers and non-specific amplification artifacts can
decrease specificity.
To overcome these disadvantages, we developed a
TaqMan two-step RT-PCR system with high sensitivity
and specificity using MGB probes to quantify the main
genotypes of aa 70. Our system cannot be used for aa 70
genotypes other than CGG/CAG, which account for
about 13% of patients with HCV 1b.
Considering the variability of HCV RNA, primers and
probes should be designed to match HCV quasispecies
as much as possible. We first determined a consensus
sequence of the HCV 1b core gene based on 489 se-
quences [20]. Primers were then designed based on con-
served regions. Our results showed that for 115 of 138
patients, the primers matched well with the HCV core
gene. Of the 23 patients with mismatched bases at the
primer sites, 22 were near the 5′ end of the primers and
had little influence on the PCR results. A single mis-
matched site (G162A) was near the 3′ end of the sense
primer and resulted in reduced PCR efficiency. Because
primer mismatches are critical to the success of qPCR
assays, primer sequences must be modified if mis-
matches are frequent. The frequencies of possible primer
mismatches, including G162A, were very low, especially
for sites near the 3′ end, and possibly lowered PCR effi-
ciency (Table 5). Therefore, the primers designed for the
system will work well for the vast majority of patients.
For the probes, because the target site was codon 70,
the only way to improve specificity is to shorten the
length of the probe. The MGB probe was the best option
because when it is hybridized to a complementary target,
the MGB molecule folds into duplex and hyper-stabilizes,
allowing the use of shorter, more specific probe sequences
[21]. Although MGB probes can detect single-base muta-
tions, the system we developed can still detect part of plas-
mid templates with one-base mismatch. The reason for
this might be because there were too many G and C
bases around codon 70, therefore the G/C to A/T ratio
in probes was too high (>80%). Reaction efficiency and
crossing threshold were lower than those in corre-
sponding plasmids. The slope of the curve for Rn vs. cy-
cles for the mismatched reactions was much lower than
those for the well-matched reactions. When the cross-
reaction control with 5 × 107 copies of one-base mis-
match plasmid was used, a manual baseline could be
moved to cover the curve vertex of the cross-reaction
control. The curves for the standards were at the expo-
nential growth stage, with parallelism between curves
still very good.When compared with the Roche diagnostic system,
which is widely used in clinics, our novel system exhibited
good comparative performance. When the system with
normal TaqMan MGB probes was used, the results for 15
patients were less than 5-fold from those of the Roche
diagnostic system. For one case, it was because there was
a mismatched site near the 3′ end of the sense primer. For
the other 14 cases, different codon 70 types (CGA, CGT,
CAA, CAT, and CAC) were identified by direct sequen-
cing. The normal probes designed for “CGG or CAG”
were not strong matches for the sequences. When our im-
proved system with degenerate probes was used, all results
were comparable with those from the Roche diagnostic
system. The degenerate probes were designed with inosine
as the third base of codon 70. Inosine can indiscriminately
pair with adenine, thymine, guanine or cytosine. This al-
lows for a probe design that spans SNPs without the poly-
morphism disrupting the annealing efficiency of probes.
To determine the proportion of patients who were suitable
for probes, the types of codon 70 for the 489 independent
HCV 1b gene sequences were analyzed. Of the codon 70
types, 87.1% are CGG and CAG, and can be effectively
tested by the system with normal TaqMan MGB probes.
CGN and CAN account for 99.6% of codon 70 types and
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ate probes (Table 6).
The detection limit of our assay (1.0 × 103 copies/mL)
was not satisfactory. To detect 1% of mutation, samples
with viral loads greater than 1.0 × 105 copies/mL would
be required. However, it is very difficult to further im-
prove sensitivity in the laboratory. Therefore, the novel
detection system is mainly for patients with viral loads
greater than 1.0 × 105 IU/mL at baseline. In many pub-
lished studies, the inclusion criteria involve viral loads
greater than 100 kIU/mL [8,13,19]. Among the 138 pa-
tients tested in the study, only the viral loads of five pa-
tients were lower than 1.0 × 105 copies/mL. Our novel
assay is useful for the majority of patients. We are now
focusing on a larger study, and our novel quantitative
detection system is expected to be useful for investigat-
ing the dynamic response of wild-types and mutants to
PEG-IFNα/RBV therapy, and the effects of R70Q/H sub-
stitutions on resistance to PEG-IFNα/RBV therapy.Conclusions
We developed a detection system for quantitatively de-
termining aa 70 substitutions in the HCV 1b core re-
gion. Our novel developed system had good sensitivity
and accuracy, and was helpful in quantifying wild-type
and mutant viral RNAs. It also provides a way to inves-
tigate the dynamic responses of wild-type and mutant
viral RNAs to PEG-IFN/RBV therapy.Methods
Ethics statement
Our study protocol conformed to the ethical guidelines
of the Declaration of Helsinki and was approved by The
Ethical Committee of Beijing Youan Hospital, Capital
Medical University. Written informed consent was ob-
tained from each patient participating in this study.Table 6 Proportions of codon 70 types among 489
independent HCV 1b gene sequences










Total 489 100Serum samples
Between January 2012 and April 2014, serum samples
were obtained from 138 Chinese patients with chronic
HCV 1b infection that had not been treated. Patients
were from the Department of Hepatology, Beijing Youan
Hospital, Capital Medical University and were used to
develop and evaluate our novel detection system. Total
viral loads were determined by TaqMan qPCR (Amplicor,
Roche Diagnostic Systems, Shanghai, China). Samples
were kept at −80°C until required.
HCV RNA extraction and reverse transcription
We extracted HCV RNA from serum samples (140 μL)
using a QIAamp Viral RNA Mini Kit according to the
manufacturer’s protocol (Qiagen, Shanghai, China). We
prepared cDNA by reverse transcription with random
hexamers and TaqMan Reverse Transcription Reagents
(Applied Biosystems). Reverse transcription reaction con-
ditions involved incubation at 25°C for 10 min, then 42°C
for 40 min, and finally 95°C for 5 min.
Plasmid DNA controls
The HCV core gene was amplified from the serum of a
patient with HCV 1b using PCR and specific primers
(5′-AAT GCC TGG AGA TTT GGG-3′ and 5′-TTG
GAG CAG TCG TTC GTG-3′). Thermal cycling condi-
tions involved denaturation at 95°C for 10 min, followed
by 40 cycles of amplification (30 s at 95°C, 30 s at 55°C,
and 1 min at 72°C) and a 7-min extension step at 72°C
after the 40th cycle. Amplicons were purified using a
QIAquick PCR Purification Kit (Qiagen) after agarose
gel electrophoresis, and then cloned into pCR-TOPO2.1
(Invitrogen) according to the manufacturer’s protocol.
Positive clones were picked and codon 70 types were
identified by sequencing (Beijing AuGCT DNA-SYN
Biotechnology Co., Ltd). The codon 70 wild-type was
CGG. We then made a plasmid carrying a mutant codon
70 (CAG). Site-directed mutagenesis was performed using
a QuikChange II Site-Directed Mutagenesis Kit (Agilent
Technologies, Santa Clara, CA, USA) according to the
manufacturer’s protocol and specific complementary
primers (5′-CAA GGC TCG CCG GCC CGA GGG
CAG GGC CTG-3′ and 5′-CAG GCC CTG CCC TCG
GGC CGG CGA GCC TTG-3′). The introduction of
the mutation was confirmed by sequencing. Plasmids con-
taining wild-type or mutant codon 70 were serially diluted
10-fold to provide a dilution range of 107–10° copies/μL.
HCV 1b core region consensus sequence and codon 70
types
We downloaded 1336 HCV 1b gene sequences, includ-
ing the full-length core region, from the European HCV
database (euHCVdb), HCV Databases from Los Alamos
National Laboratory, HCV Database (HCVdb) from the
Table 7 Primers and TaqMan MGB probes used for detection of aa 70 substitutions
Type Primer name Binding position (nt) Sequence (5′–3′)
Primers sense 148–167 AGG AAG ACT TCC GAG CGG TC
antisense 302–286 CGG GGT GAC AGG AGC CA
Degenerate probes 70 W(CGN) 203–217 FAM-CTC GCC GIC CCG AGG-MGB
70 M(CAN) 203–219 VIC-CTC GCC AIC CCG AGG GC-MGB
Normal probes 70 W(CGG) 204–217 FAM-TCG CCG GCC CGA GG-MGB
70 M(CAG) 203–218 VIC-CTC GCC AGC CCG AGG G-MGB
CR, core region; nt, nucleotides; I, inosine.
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National Center for Biotechnology Information (NCBI)
[20]. Of these, 847 sequences were excluded (814 were
from repeated cases at different time points, 19 from
cultured cells, eight from plasmids, and six from animal
experiments). The remaining 489 sequences were used
to determine the consensus sequence of the HCV 1b
core region and codon 70 types with the GENETYX
software application (Genetyx Corp., Tokyo, Japan).
Primer and TaqMan probe design for qPCR assays
Primers were synthesized by Sangon Biotech (Shanghai)
Co. Ltd. Compared with the TaqMan MGB probes for
the main types of codon 70 (CGG and CAG), inosine
was used to design two degenerate TaqMan MGB probes
for 70 W (CGN) and 70 M (CAN) (Table 7). Probes
were purchased from Invitrogen (Shanghai). We per-
formed qPCR assays in a final volume of 50 μL; each re-
action contained 5 μL of cDNA, 0.3 μM each primer,
0.1 μM probe and 25 μL of 2× LightCycler® 480 Probes
Master Mix (Roche Applied Science, Shanghai, China).
Two separate reactions were prepared to detect the
wild-types and mutants, but were simultaneously carried
out on the same thermal cycling system. Thermal cyc-
ling conditions involved an initial denaturation step at
95°C for 10 min, followed by 45 cycles of amplification
(15 s at 95°C and 1 min at 60°C). All assays were per-
formed in triplicate on a LightCycler® 480 real-time PCR
System (Roche Applied Science) and results were ana-
lyzed using LightCycler® 480 Software (Roche Applied
Science).
Nucleotide sequencing of the HCV core gene
We used direct sequencing to determine the HCV core
gene sequence from the sera of 138 patients. Nucleic
acids were amplified by PCR using specific primers
(5′-AAT GCC TGG AGA TTT GGG-3′ and 5′-TTG
GAG CAG TCG TTC GTG-3′). All samples were ini-
tially denatured at 95°C for 10 min and then subjected
to 40 cycles of amplification (30 s at 95°C, 30 s at 55°C,
and 1 min at 72°C), with an additional 7 min final ex-
tension step at 72°C. Amplicons were purified with a
QIAquick PCR Purification Kit (Qiagen) after agarosegel electrophoresis and then used for direct sequencing
(Beijing AuGCT DNA-SYN Biotechnology Co. Ltd).
The ratio of 70 W to 70 M was determined by cloning
and sequencing for some of the patients and results
compared with those for the improved system to evalu-
ate accuracy. Cloning was carried out using TOPO TA
Cloning Kits (Invitrogen) according to the manufacturer’s
protocol. We conducted PCRs using 5′-TCG TGG AAG
GCG ACA ACC-3′ and 5′-GCC GAC GAG CGG AAT
GT-3′ as sense and antisense primers, respectively. We
then randomly picked 20 colonies for each sample
and had them sequenced (Beijing AuGCT DNA-SYN
Biotechnology Co. Ltd).
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